# EDGAR Filing Document

**Accession Number:** 0001907223
**File Stem:** 0001213900-25-091661
**Filing Date:** 2025-9
**Character Count:** 11478
**Document Hash:** ecc166dd6f5c350935952f1208617b98
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-091661.hdr.sgml**: 20250925

**ACCESSION NUMBER**: 0001213900-25-091661

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250919

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250925

**DATE AS OF CHANGE**: 20250925

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Klotho Neurosciences, Inc.
- **CENTRAL INDEX KEY:** 0001907223
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 862727441
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41340
- **FILM NUMBER:** 251343997

**BUSINESS ADDRESS:**
- **STREET 1:** 13576 WALNUT STREET, SUITE A
- **CITY:** OMAHA
- **STATE:** NE
- **ZIP:** 68144
- **BUSINESS PHONE:** (833) 931-6330

**MAIL ADDRESS:**
- **STREET 1:** 13576 WALNUT STREET, SUITE A
- **CITY:** OMAHA
- **STATE:** NE
- **ZIP:** 68144

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANEW Medical, Inc.
- **DATE OF NAME CHANGE:** 20240624

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Redwoods Acquisition Corp.
- **DATE OF NAME CHANGE:** 20220127

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **September 19, 2025**

**Klotho Neurosciences, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

---

| | |
|:---|:---|
| **001-41340** | **86-2727441** |
| (Commission File Number) | (IRS Employer<br> Identification No.) |

---

1300 South Boulevard, Suite D

Charlotte, NC 28203

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (833) 931-6330

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on Which Registered** |
| Common Stock | KLTO | The Nasdaq Stock Market LLC |
| Warrants | KLTOW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 **Item 1.01. Entry Into or Amendment of a Material Definitive Agreement.**

On September 19, 2025, Klotho Neurosciences, Inc. (the "Company") entered into an Amendment (the "Amendment") to the Subscription Agreement dated June 13, 2024 by and between the Company, on the one hand and Meteora Special Opportunity Fund I, LP, Meteora Capital Partners, LP, Meteora Select Trading Opportunities Master, LP and Meteora Strategic Capital, LLC, collectively on the other hand (the "Agreement"). Pursuant to the terms of the Amendment, the term of the Agreement was extended until September 19, 2025 and the maximum number of shares applicable to the Agreement was fixed at 6,755,000.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which is filed herewith as Exhibit 4.1 and incorporated herein by reference.

**Item 9.01** **Financial Statements and Exhibits.**

<u>Exhibits</u> <u>Description</u> <br> 4.1 [Amendment](ea025884701ex4-1_klotho.htm) <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: September 25, 2025 | **KLOTHO NEUROSCIENCES, INC.** | **KLOTHO NEUROSCIENCES, INC.** |
|  | By: | /s/ Joseph Sinkule |
|  | Name: | Joseph Sinkule |
|  | Title: | Chief Executive Officer |

---

## Exhibit 4.1

**Exhibit 4.1**

**SECOND AMENDMENT TO FORWARD PURCHASE AGREEMENT CONFIRMATION** 

THIS SECOND AMENDMENT TO FORWARD PURCHASE AGREEMENT CONFIRMATION, dated as of September 19, 2025 (this "Amendment"), is entered into by and among (i) Meteora Capital Partners, LP ("<u>MCP</u>"), (ii) Meteora Select Trading Opportunities Master, LP ("<u>MSTO</u>"), (iii) Meteora Strategic Capital, LLC ("<u>MSC</u>") and (iv) Meteora Special Opportunity Fund I, LP ("<u>MSOF</u>") (with MCP, MSTO, MSC, and MSOF collectively as "<u>Seller</u>"), and (v) Klotho Neurosciences Inc. f/k/a ANEW Medical, Inc., a Wyoming corporation f/k/a Redwoods Acquisition Corp., a Delaware corporation ("<u>PubCo</u>").

Reference is hereby made to the OTC Equity Prepaid Forward Transaction, dated as of June 13, 2024 (as amended on September 19, 2024 and as may be further amended from time to time, the "<u>Confirmation</u>"), by and between Seller and PubCo. Capitalized terms not defined herein shall have the meanings assigned to such terms in the Confirmation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Amendment</u>: The parties hereto agree to amend the Confirmation as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. The section titled "Valuation Date" shall be deleted in its entirety and replaced with the following:

---

| | |
|:---|:---|
| Valuation Date: | The earlier to occur of (a) September 18, 2026, which represents approximately the date that is twenty-seven (27) months after the date of the closing of the Business Combination (the date of the closing of the Business Combination, the "**Closing Date**") pursuant to the Business Combination Agreement, dated as of May 30, 2023 (which was subsequently amended on November 4, 2023, and as may be further amended, supplemented or otherwise modified from time to time, the "**BCA**"), by and among RWOD, Merger Sub, and Target, (b) the date specified by Seller in a written notice to be delivered to Counterparty at Seller's discretion (which Valuation Date shall not be earlier than the day such notice is effective) after the occurrence of any of (v) a Shortfall Variance Registration Failure, (w) a VWAP Trigger Event, (x) a Delisting Event, (y) a Registration Failure or (z) unless otherwise specified therein, upon any Additional Termination Event, and (c) the date specified by Seller in a written notice to be delivered to Counterparty at Seller's sole discretion (which Valuation Date shall not be earlier than the day such notice is effective). The Valuation Date notice will become effective immediately upon its delivery from Seller to Counterparty in accordance with this Confirmation. |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. The section titled "Reset Price" shall be deleted in its entirety and replaced with the following:

---

| | |
|:---|:---|
| &nbsp;&nbsp; <br> Reset Price: | &nbsp;&nbsp;The Reset Price will initially be $10.00. The Reset Price will be subject to reset on a weekly basis commencing the first week following the thirtieth day after the closing of the Business Combination to be the lesser of (a) the Initial Price and (b) the VWAP Price of the Shares of the prior trading week. |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. The section titled "Dilutive Offering Reset" shall be deleted in its entirety.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. The section titled "Maximum Number of Shares" shall be deleted in its entirety and replaced with the following:

---

| | |
|:---|:---|
| &nbsp;&nbsp; <br> Maximum Number of Shares:<br>| &nbsp;&nbsp;6,755,000 Shares. For the avoidance of doubt, the Maximum Number of Shares shall be fixed and shall not be decreased or increased for any reason (other than subject to adjustments upon stock splits or stock dividends), including pursuant to any provisions of this Confirmation prior to the implementation of the Second Amendment to this Confirmation, dated as of September 19, 2025. |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>No Other Amendments</u>. All other terms and conditions of the Confirmation shall remain in full force and effect and the Confirmation shall be read and construed as if the terms of this Amendment were included therein by way of addition or substitution, as the case may be.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Execution in Counterparts</u>. This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute one and the same agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Ratification</u>. The terms and provisions set forth in this Amendment modify and supersede all inconsistent terms and provisions set forth in the Confirmation and, except as expressly modified and superseded by this Amendment, the terms and provisions of the Confirmation are ratified and confirmed and continue in full force and effect. All parties hereby agree that the Confirmation, as amended by this Amendment, shall continue to be legal, valid, binding and enforceable in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (WITHOUT GIVING EFFECT TO THE CONFLICT OF LAWS PROVISIONS THEREOF).

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed and delivered by their duly authorized officers as of the date first above written.

---

| | | | |
|:---|:---|:---|:---|
| **METEORA SELECT TRADING OPPORTUNITIES MASTER, LP; METEORA CAPITAL PARTNERS, LP; METEORA STRATEGIC CAPITAL, LLC;** and **METEORA SPECIAL OPPORTUNITY FUND I, LP** | **METEORA SELECT TRADING OPPORTUNITIES MASTER, LP; METEORA CAPITAL PARTNERS, LP; METEORA STRATEGIC CAPITAL, LLC;** and **METEORA SPECIAL OPPORTUNITY FUND I, LP** | **KLOTHO NEUROSCIENCES F/K/A ANEW MEDICAL, INC. INC.** | **KLOTHO NEUROSCIENCES F/K/A ANEW MEDICAL, INC. INC.** |
| By: | /s/ Vik Mittal | By: | /s/ Jeffrey LeBlanc |
| Name: | Vik Mittal | Name: | Jeffrey LeBlanc |
| Title: | Managing Member | Title: | Chief Financial Officer |

---